Lixisenatide (Adlyxin, Lyxumia)
Once-daily prandial GLP-1 receptor agonist with selective postprandial glucose-lowering activity.
At a glance
What it is: Once-daily prandial GLP-1 receptor agonist with selective postprandial glucose-lowering activity..
Primary research applications:
- Type 2 diabetes (with particular benefit on postprandial glucose)
Editorial summary: Lixisenatide is a shorter-acting GLP-1 receptor agonist with a clinical profile distinct from the longer-acting weekly agents. Its prandial pharmacology — strong postprandial glucose effect with less impact on fasting glucose — has carved out a specific niche in T2D management, particularly in combination with basal insulin (Soliqua / iGlarLixi).
- Class / structure
- 44-amino-acid peptide; modified exendin-4 derivative
- Half-life
- ≈ 3 hours
- First described
- Late 2000s (Sanofi)
- Regulatory status
- FDA-approved (2016)
What is Lixisenatide?
Lixisenatide is a 44-amino-acid GLP-1 receptor agonist derived from the exendin-4 backbone with C-terminal modifications that produce its specific pharmacokinetic profile.
Discovery and development
Lixisenatide was developed by Sanofi (originally as a Zealand Pharma-discovered molecule) and approved by the FDA in 2016 as Adlyxin. Although approved after the longer-acting GLP-1s had largely defined the class, lixisenatide carved out a distinctive prandial profile and was strategically paired with basal insulin glargine in the Soliqua / iGlarLixi fixed-ratio combination.
Mechanism of action
Same GLP-1 receptor agonism as the rest of the class. The clinical distinctiveness comes from short duration of action — strong gastric-emptying-slowing and postprandial-glucose effects after the dosed meal, with less sustained activity overnight or before subsequent meals.
Pharmacokinetics
Lixisenatide has a short ~3-hour half-life supporting once-daily dosing before the largest meal. Its short duration of action drives a strong postprandial effect with relatively less impact on overnight fasting glucose — distinct from longer-acting weekly agents.
What the research shows
The peer-reviewed literature on Lixisenatide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Provides postprandial glucose control in T2D | GetGoal program | Supported |
| Has cardiovascular outcomes data | ELIXA was non-inferior, not superior, for MACE | Mixed |
| Combines well with basal insulin | iGlarLixi / Soliqua data | Supported |
Reported user experiences
How the research describes administration
Once-daily subcutaneous injection within the hour before the largest meal of the day. Available also as the iGlarLixi / Soliqua fixed-ratio combination with insulin glargine.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Lixisenatide's clinical role is most coherent in combination with basal insulin (the Soliqua / iGlarLixi context) where its prandial pharmacology complements long-acting insulin. As a stand-alone agent, it has been overtaken by once-weekly semaglutide and dulaglutide for most T2D indications.
Frequently asked questions
Why use lixisenatide instead of semaglutide?
Lixisenatide's short duration is occasionally preferred in patients with prominent postprandial hyperglycemia who do not need the broader effects of longer-acting GLP-1s, and its fixed-ratio pairing with basal insulin in Soliqua is its strongest current niche. For most T2D patients with established weight or glycemic control needs, the longer-acting agents typically come first.
References
- Bolli GB, Munteanu M, et al. Efficacy and safety of lixisenatide once daily versus placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014;31(2):176-184. https://pubmed.ncbi.nlm.nih.gov/24024701/
- Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA). N Engl J Med. 2015;373(23):2247-2257. https://pubmed.ncbi.nlm.nih.gov/26630143/